Publications by authors named "Elisabetta Menatti"
Article Synopsis
- A multicentre trial named ICOS-ONE found that 27% of patients showed increased cardiac troponin levels after receiving anthracycline chemotherapy, prompting a post hoc analysis to explore long-term cardiotoxicity and monitor cardiovascular biomarkers.
- The study involved patients with no prior cardiovascular issues, showing no significant differences in biomarker levels between those receiving preventative treatment and those treated upon experiencing elevated levels.
- Over 36 months, there were no new cases of left ventricular dysfunction or elevated troponin; BNP levels remained stable, while PTX3 peaked shortly after treatment and then returned to baseline levels, indicating stable heart function overall.
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
Daniela Cardinale Fabio Ciceri Roberto Latini Maria Grazia Franzosi Maria Teresa Sandri Elisabetta Menatti
Eur J Cancer
May 2018
Background: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit.
Methods: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals.